acwy vax - powder and solvent for solution for injection meningococcal polysaccharide groupsa, c, y and w135 vaccine
smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines
acwy vax - powder and solvent for solution for injection, multidosemeningococcal polysaccharide groups a, c, y and w135 vaccine
smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines
neisvac-c
pfizer new zealand limited - neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) - suspension for injection - 10 mcg/0.5ml - active: neisseria meningitidis group c polysaccharide 10ug (polysaccharide antigen from strain c11, conjugated to tetanus toxoid) excipient: aluminium hydroxide sodium chloride tetanus toxoid water for injection - active immunisation of children from 8 weeks of age, adolescents and adults for the prevention of invasive disease caused by neisseria meningitidis serogroup c.
menquadfi
sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y.the use of this vaccine should be in accordance with available official recommendations.
menomune a/c/y/w-135 combined- neisseria meningitidis group capsular polysaccharide antigen and
sanofi pasteur inc. - neisseria meningitidis group a capsular polysaccharide antigen (unii: 1i86b47ny4) (neisseria meningitidis group a capsular polysaccharide antigen - unii:1i86b47ny4) - neisseria meningitidis group a capsular polysaccharide antigen 50 ug in 0.5 ml
menomune a/c/y/w-135 combined- neisseria meningitidis group capsular polysaccharide antigen and
sanofi pasteur inc. - neisseria meningitidis group a capsular polysaccharide antigen (unii: 1i86b47ny4) (neisseria meningitidis group a capsular polysaccharide antigen - unii:1i86b47ny4) - neisseria meningitidis group a capsular polysaccharide antigen 50 ug in 0.5 ml
nimenrix powder and solvent for solution for injection
pfizer private limited - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w-135 polysaccharide; neisseria meningitidis group y polysaccharide; tetanus toxoid carrier protein - injection, powder, for solution - 5 micrograms - neisseria meningitidis group a polysaccharide 5 micrograms; neisseria meningitidis group c polysaccharide 5 micrograms; neisseria meningitidis group w-135 polysaccharide 5 micrograms; neisseria meningitidis group y polysaccharide 5 micrograms; tetanus toxoid carrier protein ~44 micrograms
trumenba (meningococcal group b vaccine) suspension for injection pre-filled syringe
pfizer australia pty ltd - neisseria meningitidis serogroup b recombinant lipidated- factor h binding protein subfamily a, quantity: 60 microgram; neisseria meningitidis serogroup b recombinant lipidated- factor h binding protein subfamily b, quantity: 60 microgram - injection, suspension - excipient ingredients: water for injections; aluminium phosphate; histidine; sodium chloride; polysorbate 80 - trumenba is indicated in individuals 10 years and older for active immunisation to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.
neisvac-c vaccine meningococcal group c polysaccharide conjugate vaccine suspension for injection syringe
pfizer australia pty ltd - tetanus toxoid, quantity: 20 microgram/ml; meningococcal polysaccharide group c, quantity: 20 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; water for injections; aluminium hydroxide hydrate - neisvac-c vaccine is indicated for active immunisation of children from 8 weeks of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis serogroup c.
menjugate 10 micrograms suspension for injection meningococcal group c conjugate vaccine
gsk vaccines s.r.l. - meningococcal group c oligosaccharide; corynebacterium diphtheriae crm197 protein - suspension for injection in pre-filled syringe - 10 - meningococcal vaccines; other meningococcal polyvalent purified polysaccharides antigen - meningococcal vaccines - active immunisation of children from 2 months of age, adolescents and adults, for the prevention of invasive disease caused by neisseria meningitidis group c.